Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CMS Proposes To Cover CT Lung Cancer Screening, With Lengthy Criteria

This article was originally published in The Gray Sheet

Executive Summary

CMS proposed Nov. 10 to for the first time cover for lung cancer screening with low dose computed tomography in a decision applauded by imaging and lung cancer groups. The proposed decision memo includes detailed eligibility criteria for coverage including mandatory registry data collection, required patient counseling visits and provider and facility accreditation standards.

You may also be interested in...



Medicare Covers CT Lung Cancer Screening With Tweaks From Proposal

CMS issued a final decision to cover annual low-dose computed tomography (LDCT) screening scans for Medicare patients who are asymptomatic but at high risk for lung cancer, and also made several changes from the proposed NCD in patient eligibility, and registry requirements, in an action praised by the imaging industry.

Medicare Advisors Doubt Benefits Of Low-Dose CT For Lung Cancer Screening

A Medicare advisory panel voted “low confidence” on the benefits of low-dose computed tomography for lung cancer screening at an April 30 meeting in Baltimore, Md.

CT Lung Cancer Screening Is Up For National Medicare Coverage Consideration

CMS agency accepted two formal requests to open a national coverage analysis for low-dose computed tomography as a lung-cancer screening tool for high-risk, but asymptomatic individuals, and plans to hold a MedCAC meeting on the topic in April.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT033488

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel